GLP-1 Drugs: Ozempic, Wegovy, and the Demand That Is Not Going Away

Wegovy carries a list price of $1,349 per month. Ozempic lists at $1,028. At $12,000 to $16,000 annually per member on therapy, these drugs add costs that small group plans never budgeted for and cannot avoid budgeting for now. The member who begins a weight loss prescription in January changes the plan’s economics for the entire year. Three members on GLP-1 therapy in a 15-person plan add 15 to 20 percent to total expected claims.

Two years ago, the coverage question was whether to include GLP-1s at all. The SELECT trial, published in the New England Journal of Medicine in November 2023, ended that conversation. Semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20 percent in adults with cardiovascular disease and obesity without diabetes. A drug with documented mortality reduction is not a lifestyle medication. It is a cardiovascular agent with weight loss as a secondary benefit. The coverage question shifted from whether to how, and the how remains unsolved.

The Drugs and Their Pricing

#

Semaglutide, manufactured by Novo Nordisk, is marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management and cardiovascular risk reduction. Ozempic lists at approximately $1,028 per month ($12,336 annually). Wegovy lists at $1,349 per month ($16,188 annually). Net prices after rebates run lower for plans with strong PBM contracts, but the gap between list and net has narrowed as demand has outstripped payer leverage.

Tirzepatide, manufactured by Eli Lilly, is marketed as Mounjaro for type 2 diabetes and Zepbound for obesity. Tirzepatide is a dual GIP and GLP-1 receptor agonist with comparable or superior weight loss efficacy to semaglutide. List prices run $1,023 to $1,060 per month depending on dosage, similar to the semaglutide range.

The pricing trajectory is shifting. Novo Nordisk announced in February 2026 that it will reduce the list price of Wegovy by 50 percent and Ozempic by 35 percent effective January 1, 2027, setting a uniform list price of $675 per month across all semaglutide products. The reduction follows a November 2025 agreement with the White House to lower costs for Medicare, Medicaid, and self-paying patients, and reflects competitive pressure from Eli Lilly, discount pharmacy channels, and the political salience of GLP-1 pricing. For employer-sponsored plans, the 2027 list price reduction will lower the annual per-member cost from the current $12,000 to $16,000 range to approximately $8,100 at list, with net prices likely lower. The reduction is meaningful but does not eliminate the structural cost challenge for small groups, particularly as utilization continues to grow.

The FDA has expanded approved indications steadily. Wegovy gained approval for cardiovascular risk reduction in adults with obesity and established heart disease in March 2024. In August 2025, the FDA approved Wegovy for metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis. An oral formulation of Wegovy (25 mg tablet) received approval in December 2025. Each indication expansion widens the eligible population.

The Clinical Evidence

#

The SELECT trial enrolled over 17,600 adults with established cardiovascular disease and BMI of 27 or higher, without diabetes. Over a median follow-up of 40 months, participants receiving semaglutide 2.4 mg weekly experienced a 20 percent reduction in the composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke compared to placebo. The trial established semaglutide as a cardiovascular risk reduction agent, not merely a weight management drug.

The STEP trials documented weight loss efficacy. Participants on semaglutide 2.4 mg weekly lost 15 to 17 percent of body weight over 68 weeks compared to 2 to 3 percent on placebo. The SURMOUNT trials showed tirzepatide producing weight loss of 20 to 25 percent at the highest doses, approaching the efficacy of bariatric surgery in some patient populations. These weight loss results exceed any prior pharmacological intervention for obesity.

The combined evidence transforms the coverage decision. An employer who categorically excludes GLP-1 coverage must answer to employees with cardiovascular disease who are denied a drug with documented mortality reduction. Brokers positioning competing benefits packages cite GLP-1 coverage as a differentiator. Benefits consultants increasingly include GLP-1 coverage policy as a standard question in annual plan reviews. The clinical case does not solve the cost problem. It establishes that the cost must be managed, not avoided.

The weight loss data carries its own cost implication. A member who loses 15 percent of body weight on semaglutide reduces their risk profile across multiple chronic disease categories simultaneously: type 2 diabetes progression, hypertension, obstructive sleep apnea, osteoarthritis, and nonalcoholic fatty liver disease. The downstream claims savings from weight loss are real but difficult to quantify in the short planning horizon of a one-year level funded plan. The drug costs $15,000 this year. The avoided cardiovascular event or delayed diabetes progression saves the plan money two or five or ten years from now, potentially under a different carrier, a different employer, or a different coverage arrangement. The temporal mismatch between GLP-1 cost and GLP-1 benefit is a structural problem for level funded plans that renew annually.

The Demand Trajectory

#

The eligible population is large. The CDC reports that 42 percent of U.S. adults meet the clinical definition of obesity (BMI 30 or higher). An additional 31 percent have overweight (BMI 25 to 29.9). Among adults with type 2 diabetes, approximately 25 million could qualify for GLP-1 therapy under current indications. In a 25-person employer with a workforce reflecting national prevalence, approximately 10 to 11 employees meet BMI criteria for potential GLP-1 eligibility. The eligible population far exceeds current utilization even after accounting for the substantial proportion who will not seek treatment, will not receive GLP-1 prescriptions specifically, or will discontinue therapy within the first year.

The demand growth rate is steep. Evernorth’s 2025 Pharmacy in Focus report documented that nearly one-third of commercially insured households reported using GLP-1 medications, primarily for weight loss. Utilization for weight loss is projected to increase 73.1 percent by the end of 2025. GLP-1 drugs accounted for 29 percent of total net drug spending growth in 2024, single-handedly driving traditional drug spending growth from 2.1 percent in 2021 to 12.8 percent in 2024. Traditional drug trend now exceeds specialty drug trend for the first time, a structural reversal attributable almost entirely to GLP-1 demand.

Coverage patterns remain fragmented. Evernorth reported that 59 percent of fully insured health plans cover GLP-1s for weight loss, but only 22 percent of employer-sponsored plans offer the same coverage. The gap reflects employers’ cost sensitivity, particularly among small groups where a single GLP-1 prescription adds 5 to 7 percent to total claims. As clinical evidence strengthens and the 2027 list price reduction takes effect, the coverage gap will narrow. The demand trajectory points in one direction.

Competition that might provide pricing relief is years away. Novo Nordisk holds composition of matter patents on semaglutide extending through the early 2030s. Eli Lilly’s tirzepatide patents extend through 2036. Generic or biosimilar competition will eventually arrive, but the 2026 to 2032 window represents sustained demand growth at prices that, even after the announced reduction, exceed $8,000 per member per year.

For small group level funded plans, GLP-1 costs operate differently from the specialty drug exposure described in LFP-09.01. A $100,000 rare disease biologic triggers specific stop loss. GLP-1 costs do not. At $12,000 to $16,000 per member per year (declining to approximately $8,000 after the 2027 list price cut), GLP-1 prescriptions fall well below the specific stop loss attachment point of $50,000 to $100,000 typical for small groups. The cost erodes the claims fund without triggering the catastrophic protection layer. Three members on GLP-1 therapy in a 15-person plan add $36,000 to $48,000 in annual pharmacy claims. That spending compresses the aggregate corridor, the margin between expected claims and the aggregate stop loss threshold, without ever breaching the specific deductible for any individual member. The aggregate attachment point, typically set at 120 to 125 percent of expected claims, absorbs part of the GLP-1 cost increase in the current year. At renewal, the stop loss carrier resets the attachment point to reflect the new claims baseline, and the employer’s monthly contribution rises accordingly. The GLP-1 cost is permanent, not episodic. It does not resolve.

Plan Design and Pharmacy Strategies

#

Plan design cannot eliminate GLP-1 exposure. It can manage utilization and channel appropriate use. Four strategies are standard in current practice.

Prior authorization tied to clinical indications restricts coverage to FDA-approved uses. A prior authorization requiring diagnosis of type 2 diabetes with A1c above 7 percent, or BMI above 30 with documented weight-related comorbidity, or BMI above 27 with established cardiovascular disease limits coverage to members who meet clinical criteria. Prior authorization does not reduce cost for members who qualify. It prevents cosmetic or off-label use.

Step therapy requires first-line treatment before GLP-1 approval. For diabetes indications, a step requiring metformin trial before GLP-1 access ensures lower-cost therapies are attempted first. For obesity indications, step therapy may require documented participation in behavioral weight loss programs. Step therapy delays access for members who will ultimately need the high-cost drug but reduces spending on members who respond to less expensive alternatives.

Pharmacy channel optimization directs GLP-1 prescriptions through specialty pharmacy rather than retail. Specialty pharmacies may offer better contract pricing and improved adherence monitoring. The savings are modest relative to the drug cost, typically 3 to 8 percent, but meaningful in dollar terms on a $15,000 annual prescription.

Outcomes tracking ties continued coverage to demonstrated clinical response. A policy requiring 5 percent weight loss at 12 weeks, or A1c reduction of at least 0.5 percentage points, establishes a clinical threshold for ongoing coverage. Members who do not respond are tapered off therapy. Members who respond continue. Outcomes tracking ensures the plan pays only for drugs that produce measurable results.

These strategies require TPA infrastructure: prior authorization processing, pharmacy benefit coordination, outcomes monitoring across the book. For small group TPAs, building this capability across hundreds of groups produces economies that individual employers cannot achieve on their own. The structural problem persists. GLP-1 drugs at current pricing, with growing demand and no near-term generic competition, represent a permanent increase in small group plan costs. Plan design manages the increase. It does not solve it.